Ampio Pharmaceuticals (AMPE) Competitors $0.0027 0.00 (0.00%) As of 10/14/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock AMPE vs. TRVN, ARDS, NAVB, EVLO, GNCAQ, GNCA, STAB, CMRA, PXMD, and EFTRShould you be buying Ampio Pharmaceuticals stock or one of its competitors? The main competitors of Ampio Pharmaceuticals include Trevena (TRVN), Aridis Pharmaceuticals (ARDS), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Statera Biopharma (STAB), Comera Life Sciences (CMRA), PaxMedica (PXMD), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry. Ampio Pharmaceuticals vs. Its Competitors Trevena Aridis Pharmaceuticals Navidea Biopharmaceuticals Evelo Biosciences Genocea Biosciences Genocea Biosciences Statera Biopharma Comera Life Sciences PaxMedica eFFECTOR Therapeutics Trevena (NASDAQ:TRVN) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Which has more volatility & risk, TRVN or AMPE? Trevena has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Ampio Pharmaceuticals has a beta of 5.13, indicating that its stock price is 413% more volatile than the S&P 500. Which has better earnings & valuation, TRVN or AMPE? Ampio Pharmaceuticals has lower revenue, but higher earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Ampio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevena$443K0.03-$40.29M-$47.040.00Ampio PharmaceuticalsN/AN/A-$8.63M-$11.010.00 Do insiders & institutionals believe in TRVN or AMPE? 13.6% of Trevena shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 2.7% of Trevena shares are owned by company insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media prefer TRVN or AMPE? In the previous week, Trevena's average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score. Company Overall Sentiment Trevena Neutral Ampio Pharmaceuticals Neutral Do analysts recommend TRVN or AMPE? Trevena currently has a consensus price target of $5.00, indicating a potential upside of 41,566.67%. Given Trevena's stronger consensus rating and higher probable upside, equities analysts clearly believe Trevena is more favorable than Ampio Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevena 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Ampio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is TRVN or AMPE more profitable? Company Net Margins Return on Equity Return on Assets TrevenaN/A N/A -119.55% Ampio Pharmaceuticals N/A N/A N/A SummaryAmpio Pharmaceuticals beats Trevena on 6 of the 10 factors compared between the two stocks. Get Ampio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMPE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart AMPE vs. The Competition Export to ExcelMetricAmpio PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3K$1.01B$6.04B$21.90BDividend YieldN/A4.84%5.73%3.64%P/E Ratio0.001.2785.1930.09Price / SalesN/A176.74516.1665.31Price / CashN/A17.6437.5723.91Price / Book0.007.7812.424.70Net Income-$8.63M-$7.59M$3.32B$1.01B7 Day PerformanceN/A-1.26%0.80%-0.44%1 Month PerformanceN/A26.02%10.52%1.44%1 Year PerformanceN/A-10.05%76.14%15.00% Ampio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMPEAmpio PharmaceuticalsN/A$0.00flatN/A+22.7%$3KN/A0.0020TRVNTrevena1.6444 of 5 stars$0.01flat$5.00+41,566.7%-99.4%$12K$443K0.0040Gap UpARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$11KN/A0.0030Gap DownHigh Trading VolumeNAVBNavidea BiopharmaceuticalsN/AN/AN/AN/A$10K$8.13K0.0010EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070STABStatera BiopharmaN/A$0.00-50.0%N/A-50.0%$5KN/A0.0020High Trading VolumeCMRAComera Life SciencesN/AN/AN/AN/A$3K$1.00M0.002PXMDPaxMedicaN/AN/AN/A-99.9%$2KN/A0.002EFTReFFECTOR Therapeutics0.0559 of 5 stars$0.00flatN/A-99.4%$1KN/A0.0010 Related Companies and Tools Related Companies Trevena Competitors Aridis Pharmaceuticals Competitors Navidea Biopharmaceuticals Competitors Evelo Biosciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Statera Biopharma Competitors Comera Life Sciences Competitors PaxMedica Competitors eFFECTOR Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AMPE) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ampio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ampio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
